Sep 21st, 2023

Late-Breaking Science announced

See the impressive lineup of Late-Breaking Science on tap for presentation in Philadelphia.

NOTE: LBS.01 is part of the Opening General Session

8:30-9:15 a.m. (ET) | Saturday, Nov. 11 | Main Event I

Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes (SELECT)

9:45-11 a.m. (ET) | Saturday, Nov. 11 | Main Event I

Restrictive Versus Liberal Blood Transfusion in Patients With Myocardial Infarction and Anemia: Results of the MINT Trial (MINT)
Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial (ORBITA-2)
DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes (DAPA-MI)

1:30-2:45 p.m. (ET) | Saturday, Nov. 11 | Main Event I

Avoidance of Aspirin With Left Ventricular Assist Devices in Advanced Heart Failure: Primary Results of the International, Double-Blind, Placebo-Controlled ARIES HM3 Clinical Trial (ARIES HeartMate 3)
The TEAMMATE Trial: Everolimus to Prevent Rejection in Children After Cardiac Transplantation (TEAMMATE)
Integrating Cost Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Trial Providing Out-of-Pocket Costs for Heart Failure Medications During Clinical Encounters

3:15-4:30 p.m. (ET) | Saturday, Nov. 11 | Main Event I

Effects of Dietary Sodium on Systolic Blood Pressure in Middle-Aged Individuals: A Randomized Order Cross-Over Trial (CARDIA-SSBP)
Long-Term Blood Pressure Control After Physician Optimized Postpartum Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial (POP-HT)
Sustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With Hypertension (KARDIA-1)
Effectiveness of Blood Pressure-Lowering Intervention on Risk of Total Dementia Among Patients With Hypertension: A Cluster-Randomized Effectiveness Trial (CRHCP)

8-9:15 a.m. (ET) | Sunday, Nov. 12 | Main Event I

Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients With Atrial Fibrillation
Abelacimab, a Novel Factor XI/XIa Inhibitor, versus Rivaroxaban in Patients With Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial (AZALEA-TIMI 71)
Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours: The NOAH-AFNET 6 Trial (NOAH-AFNET 6)
Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation (ARTESIA)

3:30-4:45 p.m. (ET) | Sunday, Nov. 12 | Main Event I

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Recaticimab Add-On Therapy in Patients With Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia (REMAIN-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (REMAIN-2)
Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a)
Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol - Interim Results of the Phase 1b heart-1 Trial

8-9:15 a.m. (ET) | Monday, Nov. 13 | Main Event I

Hypertension Treatment in Nigeria Program: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial (HTN Program)
A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients
Effects of Intensive Blood Pressure Lowering Treatment in Reducing Risk of Cardiovascular Events (ESPRIT)
Effect of a Multifaceted Implementation Strategy on Blood Pressure Control in Low-Income Patients: A Cluster Randomized Trial (IMPACTS)

9:45-11 a.m. (ET) | Monday, Nov. 13 | Main Event I

Screening for Peripartum Cardiomyopathies Using an Artificial Intelligence Enhanced Digital Stethoscope: A Randomized Clinical Trial (SPEC-AI )
Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study (ORFAN)
Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients
Artificial Intelligence Enabled Rapid Identification of ST-Elevation Myocardial Infarction Using Electrocardiogram (ARISE): A Pragmatic Randomized Controlled Trial (ARISE)